Core Insights - Exagen Inc. has completed its 1,000,000th AVISE CTD test, highlighting its commitment to aiding patients and clinicians in managing connective tissue diseases and autoimmune conditions [1][3][4] Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focused on transforming care for patients with chronic autoimmune conditions [6] - The company's flagship product, AVISE CTD, enhances the accuracy of diagnosing complex autoimmune diseases such as lupus, rheumatoid arthritis, and Sjögren's disease [6] Product Significance - AVISE CTD offers critical information for the accurate diagnosis of autoimmune and connective tissue diseases, addressing the limitations of traditional screening methods [2] - The test has been supported by extensive peer-reviewed literature, demonstrating its clinical validity and utility in patient care [4] Market Context - The incidence of autoimmune diseases has significantly increased in recent years, creating a growing need for reliable diagnostic tools like AVISE CTD [2]
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD